适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Onkure Inc.
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Study of ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer.CTIS2023-504514-29-00Astellas Pharma Global Development Inc.240
进行中（未招募）
1 期
This is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)CTIS2022-502030-12-01Idogen AB6
进行中（未招募）
1 期
Double-blind, randomized, placebo-controlled, pilot study to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2-macrophages and mesenchymal cells (PRS CK STORM) in the prevention of COVID-19-associated cytokine stormSARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code: 10084272Term: SARS-CoV-2 infection Class: 10021881CTIS2023-507700-32-00Peaches Biotech S.L.50
进行中（未招募）
1 期
Kidney cancerMetastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864MedDRA version: 22.0Level: HLTClassification code: 10038443Term: Renal failure and impairment Class: 10038359CTIS2023-505605-16-00Oncorena AB50
进行中（未招募）
1 期
A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects with Advanced MalignanciesAdvanced MalignanciesMedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2024-514010-12-00Invox Pharma Limited131